07:19 AM EDT, 05/09/2024 (MT Newswires) -- Nuvalent ( NUVL ) reported a Q1 net loss Thursday of $0.69 per diluted share, widening from a loss of $0.44 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.67 per share.

The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended March 31.

Nuvalent ( NUVL ) said it ended Q1 with $691.8 million in cash, cash equivalents and marketable securities, sufficient to fund its operations into 2027.